Bedaquiline resistance treatment

Bedaquiline (Bedaquiline) is a drug used to treat multidrug-resistant tuberculosis (MDR-TB). However, prolonged use and inappropriate dosing may lead to bacterial resistance to bedaquiline. If a patient develops resistance to bedaquiline, resistance treatment is usually required.

Combine bedaquiline with other effective anti-tuberculosis drugs to increase the effectiveness of treatment. This increases drug exposure to bacteria and reduces the chance of bacteria developing resistance. There is evidence that bedaquiline-containing regimens are more likely to successfully treat patients with MDR-TB than bedaquiline-containing regimens. According to the patient's condition, the dose of bedaquiline is adjusted to ensure that the concentration of the drug in the body can effectively kill bacteria. This may require monitoring blood levels to determine the optimal dose, but this must be determined by the doctor. By extending the patient's treatment time to ensure that the bacteria are completely eliminated. This may require extending bedaquiline treatment to a longer cycle to increase the killing effect against resistant strains.

The drug is marketed and sold in China as daquiline fumarate tablets, and has been included in the scope of medical insurance. The common specificationsThe price of 100mg*24 tablets per box may be around 10,000 yuan, which is relatively expensive. The Russian version of bedaquiline sold overseas, Specification100mg*188 tablets per box, may cost around RMB 15,000 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of bedaquiline sold domestically and abroad are basically the same, and there are currently no generic bedaquiline drugs on the market. For specific prices and drug information of overseas drugs, please consult Yaode Medical Consultant.